A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function

Molecular Pharmacology

Volumn 52, Issue 6, 1997, Pages 1034-1040

  Oscarson, Mikael ^a   Hidestrand, Mats ^a   Johansson, Inger ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CODEINE;

AEROBIC METABOLISM; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE; GENE MUTATION; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031438162     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.6.1034     Document Type: Article

References (39)

1. Dahl, M. L., and L. Bertilsson. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61-70 (1993).
2. Spina, E., and A. P. Caputi. Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. Pharmacol. Res. 29:121-137 (1994).
3. Eichelbaum, M., and A. S. Gross. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol. Ther. 46:377-394 (1990).
4. Sindrup, S. H., and K. Brøsen. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5:335-346 (1995).
5. Rannug, A., A. K. Alexandrie, I. Persson, and M. Ingelman-Sundberg. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J. Occup. Environ. Med. 37:25-36 (1995).
6. Raunio, H., K. Husgafvel-Pursiainen, S. Anttila, E. Hietanen, A. Hirvonen, and O. Pelkonen. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 159: 113-121 (1995).
7. Mahgoub, A., J. R. Idle, L. G. Dring, R. Lancaster, and R. L. Smith. Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586 (1977).
8. Johansson, I., E. Lundqvist, L. Bertilsson, M. L. Dahl, F. Sjöqvist, and M. Ingelman-Sundberg. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90:11825-11829 (1993).
9. Alván, G., P. Bechtel, L. Iselius, and U. Gundert-Remy. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39:533-537 (1990).
10. Daly, A. K., J. Brockmöller, F. Broly, M. Eichelbaum, W. E. Evans, F. J. Gonzalez, J. D. Huang, J. R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U. A. Meyer, D. W. Nebert, V. M. Steen, C. R. Wolf, and U. M. Zanger. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201 (1996).
11. Tyndale, R., T. Aoyama, F. Broly, T. Matsunaga, T. Inaba, W. Kalow, H. V. Gelboin, U. A. Meyer, and F. J. Gonzalez. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32 (1991).
12. Johansson, I., M. Oscarson, Q. Y. Yue, L. Bertilsson, F. Sjöqvist, and M. Ingelman-Sundberg. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46: 452-459 (1994).
13. Bertilsson, L., Y. Q. Lou, Y. L. Du, Y. Liu, T. Y. Kuang, X. M. Liao, K. Y. Wang, J. Reviriego, L. Iselius, and F. Sjöqvist. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51:388-397 (1992).
14. Masimirembwa, C., J. Hasler, L. Bertilsson, I. Johansson, O. Ekberg, and M. Ingelman-Sundberg. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - reduced enzyme activity and evaluation of metabolic correlation of CYP2D6. Eur. J. Clin. Pharmacol. 51:117-122 (1996).
15. Masimirembwa, C., I. Persson, L. Bertilsson, J. Hasler, and M. Ingelman-Sundberg. a novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population-association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 42:713-719 (1996).
16. Urban, P., C. Cullin, and D. Pompon. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie 72:463-472 (1990).
17. Andersson, S., D. L. Davis, H. Dahlbäck, H. Jörnvall, and D. W. Russell. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264:8222-8229 (1989).
18. Ingelman-Sundberg, M., and H. Glaumann. Incorporation of purified components of the rabbit liver microsomal hydroxylase system into phospholipid vesicles. Biochim. Biophys. Acta 599:417-435 (1980).
19. Kronbach, T., D. Mathys, J. Gut, T. Catin, and U. A. Meyer. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162:24-32 (1987).
20. Truan, G., C. Cullin, P. Reisdorf, P. Urban, and D. Pompon. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. Gene 125:49-55 (1993).
21. Bellamine, A., J. C. Gautier, P. Urban, and D. Pompon. Chimeras of the human cytochrome P450 1A family produced in yeast. Accumulation in microsomal membranes, enzyme kinetics and stability. Eur. J. Biochem. 225:1005-1013 (1994).
22. Cullin, C., and D. Pompon. Synthesis of functional mouse cytochromes P-450 P1 and chimeric P-450 P3-1 in the yeast Saccharomyces cerevisiae. Gene 65:203-217 (1988).
23. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurements with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
24. Yasukochi, Y., and B. S. Masters. Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. hem. 251:5337-5344 (1976).
25. Omura, T., and R. Sato. The carbon monoxide-binding pigment of liver microsomes, I. Evidence of its hemoprotein nature. J. Biol. Chem. 239: 2370-2378 (1964).
26. Ladona, M. G., B. Lindström, C. Thyr, P. Dun-Ren, and A. Rane. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br. J. Clin. Pharmacol. 32:295-302 (1991).
27. Sachse, C., J. Brockmöller, S. Bauer, and I. Roots. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:284-295 (1997).
28. Aklillu, E., I. Persson, L. Bertilsson, I. Johansson, F. Rodrigues, and M. Ingelman-Sundberg. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multi-duplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278:441-446 (1996).
29. Iyun, A. O., M. S. Lennard, G. T. Tucker, and H. F. Woods. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin. Pharmacol. Ther. 40:387-394 (1986).
30. Simooya, O. O., E. Njunju, A. R. Hodjegan, M. S. Lennard, and G. T. Tucker. Debrisoquine and metoprolol oxidation in Zambians: a population study Pharmacogenetics 3:205-208 (1993).
31. Lennard, M. S., A. O. Iyun, P. R. Jackson, G. T. Tucker, and H. F. Woods. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89-92 (1992).
32. McGourty, J. C., J. H. Silas, M. S. Lennard, G. T. Tucker, and H. F. Woods. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br. J. Clin. Pharmacol. 20:555-566 (1985).
33. Koymans, L. M., N. P. Vermeulen, A. Baarslag, and G. M. Donné-Op den Kelder. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J. Comput. Aided Mol. Des. 7:281-289 (1993).
34. Modi, S., M. J. Paine, M. J. Sutcliffe, L. Y. Lian, W. U. Primrose, C. R. Wolf, and G. C. Roberts. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35:4540-4550 (1996).
35. De Groot, M. J., N. P. E. Vermeulen, J. D. Kramer, F. A. A. van Acker, and G. M. Donné-Op den Kelder. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. Chem. Res. Toxicol. 9:1079-1091 (1996).
36. Hasemann, C. A., R. G. Kurumbail, S. S. Boddupalli, J. A. Peterson, and J. Deisenhofer. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3:41-62 (1995).
37. Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:83-90 (1992).
38. Koymans, L., N. P. Vermeulen, S. A. van Acker, J. M. te Koppele, J. J. Heykants, K. Lavrijsen, W. Meuldermans, and G. M. Donné-Op den Kelder. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res Toxicol. 5:211-219 (1992).
39. Ellis, S. W., G. P. Hayhurst, G. Smith, T. Lightfoot, M. M. Wong, A. P. Simula, M. J. Ackland, M. J. Sternberg, M. S. Lennard, G. T. Tucker, and C. R. Wolf. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 270: 29055-29058 (1995).